Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Final Takeaway BPC-157 is a promising laboratory molecule, not a proven medical treatment
- What is the current evidence for the use of BPC 157
intravenous TB-4 Phase 1 safety and pharmacokinetics, no dose-limiting or serious adverse events (Ann N Y Acad Sci 2010;1194:223229): NCT00743769 On February 27, 2026, HHS Secretary Kennedy announced that GHK-Cu is among approximately 14 peptides expected to return to Category 1
By influencing processes such as collagen regulation, vascular growth, and cellular protection, BPC-157 offers a versatile platform for research into tissue repair, recovery, and systemic resilience within experimental settings
D. C. Morris, M. Chopp, L. Zhang, and Z. G. Zhang, Thymosin 4: a candidate for treatment of stroke?, Wiley, May 2010. doi: 10.1111/j.1749-6632.2010.05469.x
